Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Thomas Website

Anish Thomas, M.D.

Selected Publications

1)  Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Ann. Oncol. 24: 2601-6, 2013.
2)  Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman AW, Choyke P, Szabo E, Rajan A, Giaccone G.
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.
Clin. Cancer Res. 19: 1487-93, 2013.
3)  Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G.
Characterization and management of cardiac involvement of thymic epithelial tumors.
J Thorac Oncol. 8: 246-9, 2013.
4)  Thomas A, Hassan R.
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Lancet Oncol. 13: e301-10, 2012.
5)  Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O.
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood. 119: 2731-7, 2012.
6)  Landgren O, Thomas A, Mailankody S.
Myeloma and second primary cancers.
N. Engl. J. Med. 365: 2241-2, 2011.
7)  Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
Clin Lung Cancer. 14: 452-6, 2013.
8)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
9)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
10)  Jakopovic M, Thomas A, Lopez-Chavez A.
From platinum compounds to targeted therapies in advanced thoracic malignancies.
Anticancer Res. 34: 477-82, 2014.
11)  Thomas A, Maltzman J, Hassan R.
Farletuzumab in lung cancer.
Lung Cancer. 80: 15-8, 2013.
12)  Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Am. J. Pathol. 182: 1065-77, 2013.
13)  Tiseo M, Rajan A, Thomas A, Giaccone G.
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
J Thorac Oncol. 8: 511-2, 2013.
14)  Thomas A, Rajan A, Giaccone G.
Tyrosine kinase inhibitors in lung cancer.
Hematol. Oncol. Clin. North Am. 26: 589-605, viii, 2012.
15)  Denz CR, Zhang C, Jia P, Du J, Huang X, Dube S, Thomas A, Poiesz BJ, Dube DK.
Absence of mutation at the 5"-upstream promoter region of the TPM4 gene from cardiac mutant axolotl (Ambystoma mexicanum).
Cardiovasc. Toxicol. 11: 235-43, 2011.
16)  Thomas A, Rajan S, Thurston HL, Masineni SN, Dube P, Bose A, Muthu V, Dube S, Wieczorek DF, Poiesz BJ, Dube DK.
Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscle.
J. Cell. Biochem. 110: 875-81, 2010.
17)  Thomas A, Stein CK, Gentile TC, Shah CM.
Isolated CNS relapse of CML after bone marrow transplantation.
Leuk. Res. 34: e113-4, 2010.
18)  Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, Loughran T, Ferrer J, Sheremata W, Glaser J, Leon-Ponte M, Poiesz BJ.
LGL leukemia and HTLV.
AIDS Res. Hum. Retroviruses. 26: 33-40, 2010.
19)  Perzova R, Benz P, Abbott L, Welch C, Thomas A, El Ghoul R, Sanghi S, Nara P, Glaser J, Siegal FP, Dosik H, Poiesz BJ.
Short communication: no evidence of HTLV-3 and HTLV-4 infection in New York State subjects at risk for retroviral infection.
AIDS Res. Hum. Retroviruses. 26: 1229-31, 2010.
20)  Thomas A, James BR, Landsberg D.
Colonic necrosis due to oral kayexalate in a critically-ill patient.
Am. J. Med. Sci. 337: 305-6, 2009.
21)  Thurston HL, Prayaga S, Thomas A, Guharoy V, Dube S, Poiesz BJ, Dube DK.
Expression of Nkx2.5 in wild type, cardiac mutant, and thyroxine-induced metamorphosed hearts of the Mexican axolotl.
Cardiovasc. Toxicol. 9: 13-20, 2009.
22)  Thomas A, Lenox R.
Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult.
CMAJ. 179: 338-40, 2008.
23)  Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE.
Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy.
Front Oncol. 3: 261, 2013.
24)  Khozin S, Roth MJ, Rajan A, Smith K, Thomas A, Berman A, Giaccone G.
Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.
J Thorac Oncol. 7: e29-31, 2012.
25)  Komiya T, Thomas A, Khozin S, Rajan A, Wang Y, Giaccone G.
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.
J. Clin. Oncol. 30: 3425-6; author reply 3426, 2012.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/7/2014.